0001193125-18-301322.txt : 20181018 0001193125-18-301322.hdr.sgml : 20181018 20181017213105 ACCESSION NUMBER: 0001193125-18-301322 CONFORMED SUBMISSION TYPE: POS EX PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20181018 DATE AS OF CHANGE: 20181017 EFFECTIVENESS DATE: 20181018 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PhaseBio Pharmaceuticals Inc CENTRAL INDEX KEY: 0001169245 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 030375697 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: POS EX SEC ACT: 1933 Act SEC FILE NUMBER: 333-227474 FILM NUMBER: 181127476 BUSINESS ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY STREET 2: SUITE 30 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: (610) 981-6500 MAIL ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY STREET 2: SUITE 30 CITY: MALVERN STATE: PA ZIP: 19355 FORMER COMPANY: FORMER CONFORMED NAME: Phase Biosciences Inc DATE OF NAME CHANGE: 20061013 FORMER COMPANY: FORMER CONFORMED NAME: DT BIOSCIENCES INC DATE OF NAME CHANGE: 20020315 POS EX 1 d669557dposex.htm POS EX POS EX

As filed with the Securities and Exchange Commission on October 18, 2018.

Registration Statement No. 333-227474

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

Post-Effective

Amendment No. 1

to

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

PHASEBIO PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   2834   03-0375697

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

1 Great Valley Parkway, Suite 30

Malvern, Pennsylvania 19355

(610) 981-6500

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

Jonathan P. Mow

Chief Executive Officer

PhaseBio Pharmaceuticals, Inc.

Regus Del Mar

12707 High Bluff Drive

Suite 200

San Diego, CA 92130

(610) 981-6500

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

 

Christian E. Plaza

Darren K. DeStefano

Madison A. Jones

Cooley LLP

11951 Freedom Drive

Reston, Virginia 20190

(703) 456-8000

 

Edwin M. O’Connor

Seo Salimi

Goodwin Procter LLP

620 Eighth Avenue

New York, New York 10018

(212) 813-8800

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

 

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, check the following box.  ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering.  ☒ (333-227474)

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer  ☐           Accelerated Filer  ☐           Non-accelerated Filer  ☒           Smaller Reporting Company  ☐
      Emerging Growth Company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☒

 

 

This post-effective amendment shall become effective upon filing in accordance with Rule 462(d) promulgated under the Securities Act of 1933, as amended.

 

 

 


EXPLANATORY NOTE

This Post-Effective Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-227474) is filed pursuant to Rule 462(d) solely to add an updated Exhibit 5.1 with respect to such Registration Statement.



SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Malvern, Pennsylvania, on the 18th day of October, 2018.

 

 

PHASEBIO PHARMACEUTICALS, INC.

By:   /s/ Jonathan P. Mow
  Jonathan P. Mow
 

Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

        Signature

  

        Title

 

        Date

 /s/ Jonathan P. Mow

 Jonathan P. Mow

  

Chief Executive Officer and Director

(Principal Executive Officer)

  October 18, 2018

 /s/ John Sharp

 John Sharp

  

Chief Financial Officer

(Principal Financial Officer and Principal

Accounting Officer)

  October 18, 2018

*

 Clay B. Thorp

   Chairman of the Board of Directors   October 18, 2018

*

 Nancy J. Hutson, Ph.D.

   Director   October 18, 2018

*

 Peter Justin Klein, M.D., J.D.

   Director   October 18, 2018

*

 Caroline Loewy

   Director   October 18, 2018

*

 Bibhash Mukhopadhyay, Ph.D.

   Director   October 18, 2018

*

 Linda Tufts

   Director   October 18, 2018

 

*By:  

/s/ Jonathan P. Mow

  
  Jonathan P. Mow   
  Attorney-in-fact   
EX-5.1 2 d669557dex51.htm EX-5.1 EX-5.1

Exhibit 5.1

 

LOGO

 

Darren K. DeStefano

T: 703 456 8034

ddestefano@cooley.com

October 17, 2018

PhaseBio Pharmaceuticals, Inc.

1 Great Valley Parkway

Suite 30

Malvern, Pennsylvania 19355

Ladies and Gentlemen:

We have acted as counsel to PhaseBio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the filing by the Company of a Registration Statement (No. 333-227474) on Form S-1 (the “Registration Statement”) with the Securities and Exchange Commission, including a related prospectus filed with the Registration Statement (the “Prospectus”), covering an underwritten public offering of up to 10,580,000 shares of the Company’s common stock (the “Shares”), par value $0.001 per share, including up to 1,380,000 Shares that may be sold pursuant to the exercise of an over-allotment option to be granted to the underwriters.

In connection with this opinion, we have (i) examined and relied upon (a) the Registration Statement and the Prospectus, (b) the Company’s Amended and Restated Certificate of Incorporation and Bylaws, each as amended and in effect as of the date hereof, (c) the forms of the Company’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, filed as Exhibits 3.2 and 3.4 to the Registration Statement, respectively, each of which are to be in effect before the closing of the offering contemplated by the Registration Statement, and (d) the originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below, and (ii) assumed that the Amended and Restated Certificate of Incorporation referred to in clause (i)(c) will be filed with the Secretary of State of the State of Delaware before the closing of the offering contemplated by the Registration Statement.

We have assumed the genuineness and authenticity of all documents submitted to us as originals and the conformity to originals of all documents submitted to us as copies and the due execution and delivery, other than by the Company, of all documents where due execution and delivery are a prerequisite to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not sought independently to verify such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued against payment therefor as described in the Registration Statement and the Prospectus, will be validly issued, fully paid and non-assessable.

 

ONE FREEDOM SQUARE, RESTON TOWN CENTER, 11951 FREEDOM DRIVE, RESTON, VA 20190-5656 T: (703) 456-8000 F: (703) 456-8100 WWW.COOLEY.COM


We consent to the reference to our firm under the caption “Legal Matters” in the Prospectus included in the Registration Statement and to the filing of this opinion as an exhibit to the Registration Statement.

Sincerely,

 

Cooley LLP
By:   /s/ Darren K. DeStefano
       Darren K. DeStefano

 

ONE FREEDOM SQUARE, RESTON TOWN CENTER, 11951 FREEDOM DRIVE, RESTON, VA 20190-5656 T: (703) 456-8000 F: (703) 456-8100 WWW.COOLEY.COM

GRAPHIC 3 g669557g1003085726081.jpg GRAPHIC begin 644 g669557g1003085726081.jpg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end